Accuray (NASDAQ:ARAY) Issues Quarterly Earnings Results

by · The Cerbat Gem

Accuray (NASDAQ:ARAY – Get Free Report) posted its quarterly earnings data on Wednesday. The medical equipment provider reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04), Zacks reports. Accuray had a negative net margin of 3.48% and a negative return on equity of 33.65%. The firm had revenue of $101.55 million for the quarter, compared to analysts’ expectations of $98.10 million. During the same period in the previous year, the company posted ($0.03) EPS. Accuray updated its FY 2025 guidance to EPS.

Accuray Stock Up 3.0 %

Shares of NASDAQ:ARAY traded up $0.06 during trading on Thursday, reaching $2.09. 1,645,853 shares of the company traded hands, compared to its average volume of 483,350. The firm has a fifty day simple moving average of $1.89 and a 200 day simple moving average of $1.84. The firm has a market cap of $209.56 million, a P/E ratio of -13.06 and a beta of 1.40. Accuray has a 1-year low of $1.40 and a 1-year high of $3.05. The company has a quick ratio of 0.95, a current ratio of 1.66 and a debt-to-equity ratio of 3.65.

Accuray Company Profile

(Get Free Report)

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

Recommended Stories